Recent Finacing
Recent Raise
Tensha Therapeutics develops small-molecule bromodomain inhibitors licensed from the Bradner lab to advance a preclinical BRD4-targeting compound for BRD4-NUT carcinoma, AML, multiple myeloma, and inflammatory and metabolic indications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor